Please ensure Javascript is enabled for purposes of website accessibility

Merck's Q2 Sales Got Clobbered by COVID-19, but Still Beat Estimates

By Keith Speights – Jul 31, 2020 at 11:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Solid performances by the big drugmaker's cancer drugs helped offset headwinds from the pandemic.

So far, 2020 has not turned out like Merck (MRK -0.83%) hoped it would: The big drugmaker's blockbuster oncology treatment Keytruda flopped in late-stage studies targeting bladder cancer and small-cell lung cancer. As a result of these setbacks, as well as the COVID-19 pandemic, Merck's shares declined, and remained down more than 10% year to date as of the market close on Thursday.

However, shareholders could now have reason to smile again, based on the second-quarter results Merck released before the market opened on Friday. Here are the highlights from that update.

Male scientist in lab holding a test tube.

Image Source: Getty Images.

By the numbers

Merck reported revenue in the second quarter of $10.9 billion, down 8% year over year. However, that total was well above analysts' average estimate of $10.4 billion.

The company announced net income of $3 billion, or $1.18 per share, in the second quarter based on generally accepted accounting principles (GAAP). In the prior-year period, Merck generated GAAP earnings of $2.7 billion, or $1.03 per share.

Merck posted non-GAAP adjusted net income of $1.37 per share, a 6% year-over-year increase. This result handily beat the consensus Wall Street adjusted earnings estimate of $1.04 per share.

Behind the numbers

The COVID-19 pandemic hit Merck's vaccine business especially hard as patients largely chose not to visit healthcare providers for any but the most acute or life-threatening issues. Sales of the HPV vaccines Gardasil/Gardasil 9 sank 26% year over year in Q2 to $656 million. The sales total for its pediatric vaccines Proquad, M-M-R II, and Varivax plunged 44% to $378 million.

It was a similar story with several of the company's other products. Sales for its neuromuscular blockade reversal drug Bridion slid 18% to $224 million. Sales of the HIV drug Isentress fell 21% to $196 million. And sales for cholesterol drug Zetia/Vytorin dropped 23% to $175 million.

Even Merck's animal health unit was impacted by the pandemic, with revenue slipping 2% year over year to $1.1 billion. The company reported lower demand for livestock products as a result of restaurant and school closures during coronavirus-related lockdowns. Sales of its companion animal vaccines also as veterinary visits declined due to the pandemic.

There were a few bright spots, though. Sales of cancer immunotherapy Keytruda jumped 29% year over year to $3.4 billion. Merck's income from the sales of ovarian cancer drug Lynparza, which it co-markets with AstraZeneca, soared 61% to $178 million. Its portion of the sales for cancer drug Lenvima, which is marketed by Eisai, vaulted 57% to $151 million.

Merck's bottom line improved in the second quarter, thanks mainly to spending decreases related to the COVID-19 pandemic. Its expenses in the sales, general, and administrative category fell 12% year over year to $2.4 billion. Research and development expenses declined 3% to $2.1 billion.

Looking ahead

The rest of the year should be better for Merck. The company boosted and narrowed its full-year 2020 guidance. It now anticipates revenue will be between $47.2 billion and $48.7 billion, up from its previous guidance range of $46.1 billion to $48.1 billion. Merck projects GAAP earnings per share will be between $4.58 and $4.73, an increase from its previous forecast of $4.12 to $4.32. Non-GAAP EPS is expected to be between $5.63 and $5.78, up from its previous guidance range of $5.17 to $5.37.

While the pandemic could continue to be a headwind for the big pharmaceutical company, its efforts in the fight against the novel coronavirus could also bear fruit. It's collaborating with IAVI on the development of COVID-19 vaccine candidate V590; clinical studies for it are expected to start later this year. Merck also acquired Themis and is accelerating the development of another COVID-19 vaccine candidate, V591. Clinical testing of V591 is scheduled to begin in the current quarter.

Merck is also awaiting a couple of important regulatory decisions. It hopes to win FDA approval for the use of Keytruda as a treatment for relapsed or refractory classical Hodgkin lymphoma; that decision is expected by Oct. 30. The FDA is also scheduled to make an approval decision by Nov. 28 regarding Keytruda in combination with chemotherapy in treating triple-negative breast cancer. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$86.78 (-0.83%) $0.73
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$54.58 (-3.07%) $-1.73
Eisai Co., Ltd. Stock Quote
Eisai Co., Ltd.
$39.75 (-3.19%) $-1.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.